Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA COVID-19 vaccine monovalent XBB.1.5
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
An updated monovalent COVID-19 vaccine formulation whose antigen encodes spike protein sequence from the Omicron XBB.1.5 lineage to broaden neutralizing antibodies against XBB-descendant variants. It is delivered as an mRNA vaccine in lipid nanoparticles for Pfizer-BioNTech and Moderna products, and as a protein subunit with Matrix-M adjuvant for Novavax. Mechanism: translated spike protein induces adaptive immunity, generating neutralizing antibodies and T-cell responses that reduce risk of severe COVID-19. Indication: active immunization to prevent COVID-19 across authorized age groups, primarily for seasonal 2023-2024 use aligned with circulating variants.
- Brand names
- Comirnaty Omicron XBB.1.5Spikevax XBB.1.5Novavax COVID-19 Vaccine XBB.1.5
- Other names
- 2023-2024 COVID-19 vaccine XBB.1.5monovalent XBB.1.5-adapted COVID-19 vaccineOmicron XBB.1.5-adapted monovalent COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA COVID-19 vaccine monovalent XBB.1.5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA COVID-19 vaccine monovalent XBB.1.5.